{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:07:32Z","timestamp":1791594452582,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,7,26]],"date-time":"2004-07-26T00:00:00Z","timestamp":1090800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To determine the minimum effective dose and safety of micafungin in the treatment of HIV\u2010related oesophageal candidiasis.<\/jats:p><jats:p><jats:bold>Method<\/jats:bold> :\u2002A total of 120 patients were enrolled in this open label study of the effects of daily 1\u2003h infusions of micafungin on endoscopically proven fungal oesophagitis. Patients were randomly assigned to receive 12.5, 25, 50, 75 and 100\u2003mg of micafungin daily. Response was evaluated clinically and endoscopically.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002The protocol defined minimum effective dose of micafungin was 12.5\u2003mg. The percentage of patients experiencing clearing of physical signs and symptoms showed a dose\u2013response relationship and reached 94.7% in the 100\u2003mg dose group. All patients in the 50, 75 and 100\u2003mg dose groups achieved an endoscopically verified improvement in oesophagitis. Adverse effects of micafungin were generally mild and not dose\u2010related. No serious renal, hepatic or drug\u2010related infusion reactions were encountered.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> :\u2002Micafungin was found to be effective, well\u2010tolerated and safe. The minimum effective dose was found to be 12.5\u2003mg and a significant linear trend in the successful treatment of oesophageal candidiasis was observed across the doses used with 75 and 100\u2003mg dose levels achieving high rates of clinical and endoscopic cure.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.02083.x","type":"journal-article","created":{"date-parts":[[2004,8,5]],"date-time":"2004-08-05T15:23:16Z","timestamp":1091719396000},"page":"475-481","source":"Crossref","is-referenced-by-count":64,"title":["Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent"],"prefix":"10.1111","volume":"20","author":[{"given":"K.","family":"Pettengell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mynhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kluyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Facklam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Buell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the FK463 South African Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,7,26]]},"reference":[{"key":"e_1_2_17_2_2","first-page":"357","volume-title":"Textbook of AIDS Medicine","author":"Powderly WG.","year":"1999"},{"key":"e_1_2_17_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-7-199604010-00003"},{"key":"e_1_2_17_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90868-1"},{"key":"e_1_2_17_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90241-1"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.279"},{"key":"e_1_2_17_7_2","first-page":"539","volume-title":"The Esophagus","author":"Wilcox CM.","year":"1999"},{"key":"e_1_2_17_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922299309900"},{"key":"e_1_2_17_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199105000-00007"},{"key":"e_1_2_17_10_2","first-page":"167","volume-title":"Current Therapy of Infectious Disease","author":"Xie QY","year":"2001"},{"key":"e_1_2_17_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1994.10.925"},{"key":"e_1_2_17_12_2","first-page":"728","volume-title":"Current Therapy of Infectious Disease","author":"Perea S","year":"2001"},{"key":"e_1_2_17_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/516353"},{"key":"e_1_2_17_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/514028"},{"key":"e_1_2_17_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/516315"},{"key":"e_1_2_17_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/515554"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/313749"},{"key":"e_1_2_17_18_2","first-page":"339","volume-title":"Cancer Treatment","author":"Rhew DC","year":"2001"},{"issue":"1","key":"e_1_2_17_19_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/mmy.38.1.335.347","article-title":"New targets and delivery systems for antifungal therapy","volume":"38","author":"Walsh TJ","year":"2000","journal-title":"Med Mycol"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/313748"},{"key":"e_1_2_17_21_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.55.219"},{"key":"e_1_2_17_22_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-2-120"},{"key":"e_1_2_17_23_2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.44.2.368-377.2000","article-title":"Discovery of a novel antifungal (1,3)\u2010 \u03b2\u2010D\u2010glucan synthase inhibitors","volume":"44","author":"Onishi J","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_17_24_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/AAC.44.1.57-62.2000","article-title":"In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi","volume":"44","author":"Tawara S","year":"2000","journal-title":"Antimicrobial Agents Chemother"},{"key":"e_1_2_17_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3149-3154.2003"},{"key":"e_1_2_17_26_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jac\/46.3.485","article-title":"In vitro antifungal activity of FK463, a new water\u2010soluble echinocandin\u2010like lipopeptide","volume":"46","author":"Mikamo H","year":"2000","journal-title":"J Antimicrobial Chemother"},{"key":"e_1_2_17_27_2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.7164\/antibiotics.53.1175","article-title":"In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens","volume":"53","author":"Uchida K","year":"2000","journal-title":"J Antibiot"},{"key":"e_1_2_17_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1857-1869.2002"},{"key":"e_1_2_17_29_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.44.3.614-618.2000","article-title":"Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis","volume":"44","author":"Ikeda F","year":"2000","journal-title":"Antimicrobial Agents Chemother"},{"key":"e_1_2_17_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/323401"},{"key":"e_1_2_17_31_2","volume-title":"Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers","author":"Azuma J","year":"1998"},{"key":"e_1_2_17_32_2","volume-title":"Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients","author":"Hiemenz J","year":"1999"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02083.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02083.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.02083.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:22:22Z","timestamp":1697232142000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.02083.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,26]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1111\/j.1365-2036.2004.02083.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02083.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,26]]}}}